Assessing anxiety in C57BL/6J mice: A pharmacological characterization of the zero maze test

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 2, 2013, Pages 275-283

  Heredia, Luis ^a   Torrente, Margarita ^a   Colomina, María T ^a   Domingo, José L ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Anxiety; C57BL 6J mice; Chlordiazepoxide; Methylphenidate; Picrotoxine; Zero maze test

Indexed keywords

4 AMINOBUTYRIC ACID; CHLORDIAZEPOXIDE; METHYLPHENIDATE; PICROTOXIN; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DOSE COMPARISON; GABAERGIC SYSTEM; MALE; MAZE TEST; MOUSE; NONHUMAN; PHYSICAL ACTIVITY; SEDATION; TRANQUILIZING ACTIVITY; VIDEORECORDING; ZERO MAZE TEST;

ANIMALIA; MUS;

ANXIETY; C57BL/6J MICE; CHLORDIAZEPOXIDE; METHYLPHENIDATE; PICROTOXINE; ZERO MAZE TEST;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLORDIAZEPOXIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; PICROTOXIN; SPECIES SPECIFICITY;

EID: 84882884087     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.02.010     Document Type: Article

References (42)

1. Auden W.H. The age of anxiety: A baroque eclogue 1947, Random House, New York.
2. Bakshi V.P., Kalin N.H. Animal models and endophenotypes of anxiety and stress disorders. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 883-900. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Biala G., Kruk M. Amphetamine-induced anxiety-related behavior in animal models. Pharmacological Reports 2007, 59:636-644.
4. Bourin M., Petit-Demouliere B., Dhonnchadha B.N., Hascoet M. Animal models of anxiety in mice. Fundamental and Clinical Pharmacology 2007, 21:567-574.
5. Bouwknecht J.A., Paylor R. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behavioural Pharmacology 2008, 19:385-402.
6. Clement Y., Chapouthier G. Biological bases of anxiety. Neuroscience and Biobehavioral Reviews 1998, 22:623-633.
7. Clenet F., Hascoet M., Fillion G., Galons H., Bourin M. Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behavioural Brain Research 2005, 158:339-348.
8. Cook M.N., Crounse M., Flaherty L. Anxiety in the elevated zero-maze is augmented in mice after repeated daily exposure. Behavior Genetics 2002, 32:113-118.
9. Crawley J.N. Unusual behavioral phenotypes of inbred mouse strains - Commentary. Trends in Neurosciences 1996, 19:181-182.
10. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus-maze are confounded by increases in locomotor-activity. Psychopharmacology 1995, 118:316-323.
11. Finn D.A., Rutledge-Gorman M.T., Crabbe J.C. Genetic animal models of anxiety. Neurogenetics 2003, 4:109-135.
12. Francis J.L., Moitra E., Dyck I., Keller M.B. The impact of stressful life events on relapse of generalized anxiety disorder. Depression and Anxiety 2012, 29:386-391.
13. Hart P.C., Bergner C.L., Smolinsky A.N., Dufour B.D., Egan R.J., Laporte J.L., et al. Experimental models of anxiety for drug discovery and brain research. Methods in Molecular Biology 2010, Vol. 602:299-321.
14. Hascoet M., Bourin M. A new approach to the light/dark test procedure in mice. Pharmacology Biochemistry and Behavior 1998, 60:645-653.
15. Heredia L., Torrente M., Domingo J.L., Colomina M.T. Individual housing and handling procedures modify anxiety levels of Tg2576 mice assessed in the zero maze test. Physiology and Behavior 2012, 107:187-191.
16. Holmes A., Iles J.P., Mayell S.J., Rodgers R.J. Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behavioural Brain Research 2001, 122:159-167.
17. Ihne J.L., Fitzgerald P.J., Hefner K.R., Holmes A. Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice. Neuropharmacology 2012, 62:464-473.
18. Imaizumi M., Suzuki T., Machida H., Onodera K. A fully automated apparatus for a light/dark test measuring anxiolytic or anxiogenic effects of drugs in mice. Japanese Journal of Psychopharmacology 1994, 14:83-91.
19. Kalueff A.V., Tuohimaa P. Experimental modeling of anxiety and depression. Acta Neurobiologiae Experimentalis 2004, 64:439-448.
20. Kessler R.C., Aguilar-Gaxiola S., Alonso J., Chatterji S., Lee S., Ormel J., et al. The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys. Epidemiologia e Psichiatria Sociale 2009, 18:23-33.
21. Kessler R.C., Avenevoli S., Costello E.J., Georgiades K., Green J.G., Gruber M.J., et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Archives of General Psychiatry 2012, 69:372-380.
22. Kessler R.C., Wang P.S. The descriptive epidemiologv of commonly occurring mental disorders in the United States. Annual Review of Public Health 2008, 29:115-129.
23. Kulkarni S.K., Singh K., Bishnoi M. Elevated zero maze: A paradigm to evaluate antianxiety effects of drugs. Methods and Findings in Experimental and Clinical Pharmacology 2007, 29:343-348.
24. Kulkarni S.K., Singh K., Bishnoi M. Comparative behavioural profile of newer antianxiety drugs on different mazes. Indian Journal of Experimental Biology 2008, 46:633-638.
25. Laarakker M.C., van Lith H.A., Ohl F. Behavioral characterization of A/J and C57BL/6J mice using a multidimensional test: Association between blood plasma and brain magnesium-ion concentration with anxiety. Physiology and Behavior 2011, 102:205-219.
26. Lakoff A. The mousetrap: managing the placebo effect in antidepressant trials. Molecular Interventions 2002, 2:72-76.
27. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
28. Mathiasen L.S., Mirza N.R., Rodgers R.J. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice. Pharmacology Biochemistry and Behavior 2008, 90:19-36.
29. Montgomery K.C., Monkman J.A. The relation between fear and exploratory behavior. Journal of Comparative and Physiological Psychology 1955, 48:132-136.
30. Niculescu M., Ehrlich M.E., Unterwald E.M. Age-specific behavioral responses to psychostimulants in mice. Pharmacology Biochemistry and Behavior 2005, 82:280-288.
31. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
32. Ressler K.J. Amygdala activity, fear, and anxiety: modulation by stress. Biological Psychiatry 2010, 67:1117-1119.
33. Reynolds D.S., McKernan R.M., Dawson G.R. Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved.?. Trends in Pharmacological Sciences 2001, 22:402-403.
34. Rodgers R.J., Davies B., Shore R. Absence of anxiolytic response to chlordiazepoxide in two common background strains exposed to the elevated plus-maze: Importance and implications of behavioural baseline. Genes, Brain, and Behavior 2002, 1:242-251.
35. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 1994, 116:56-64.
36. Shrout P.E., Fleiss J.L. Intraclass correlations - Uses in assessing rater reliability. Psychological Bulletin 1979, 86:420-428.
37. Tang X.D., Xiao J.H., Parris B.S., Fang J.D., Sanford L.D. Differential effects of two types of environmental novelty on activity and sleep in BALB/cJ and C57BL/6J mice. Physiology and Behavior 2005, 85:419-429.
38. Troelsen K.B., Nielsen E.O., Mirza N.R. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: The role of the serotonin transporter. Psychopharmacology 2005, 181:741-750.
39. Venault P., Chapouthier G., Prado de Carvalho L., Rossier J. Effects of convulsant ligands of the GABA-benzodiazepine receptor complex in conflict and learning tasks in mice. L'Encéphale 1992, 18:655-660.
40. Weiss S.M., Wadsworth G., Fletcher A., Dourish C.T. Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety. Neuroscience and Biobehavioral Reviews 1998, 23:265-271.
41. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011, 21:655-679.
42. Yilmazer-Hanke D.M., Roskoden T., Zilles K., Schwegler H. Anxiety-related behavior and densities of glutamate, GABA(A), acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains. Behavioural Brain Research 2003, 145:145-159.